RxDoctor Payments Data

Christopher Haydek, MD

Gastroenterology · Castle Rock, CONPI 1164963336

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $105,025 of the $111,535 with a category attached, or 94.2%. Capsovision, Inc. accounts for 94.2% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $107,740, more than ten times the $923 reported in 2023. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$111,535in general payments, 2019–2025

Across 288 payments — averaging $387.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Capsovision, Inc.$105K
  • AbbVie$2K
  • Johnson & Johnson$627
  • Takeda Pharmaceuticals U.S.A., Inc.$602
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$531
  • Sanofi$512
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$105,02594%
  • Food & beverage$6,4426%
  • Education$690%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,535 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$52,497
Medicare patients
180
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase17$40,649
SutabSod Sulf/Pot Chloride/Mag Sulf68$11,068
Omeprazole148$3,299
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag19$2,419
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$1,148
Esomeprazole Magnesium11$378
Famotidine14$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$1,590$40,64917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Castle Rock

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →